NGM·Healthcare·$232M·#19 / 520 in Healthcare
KROS Keros Therapeutics, Inc.
77SOLID
CATEGORY BREAKDOWN
GROWTH100
QUALITY40
STABILITY99
VALUATION100
GOVERNANCE53
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+6775.0%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
5.6%
96
< 25% strong
Price / Sales
Market cap relative to trailing revenue
0.9x
100
< 3x strong
Rule of 40
Growth rate plus operating margin
6803
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.6%
29
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-51.2%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE KROS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when KROS's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.